#Japan #Tokyo #Sky Labs #CART BP pro #Otsuka Pharmaceutical

Exclusive Distribution Agreement for CART BP pro in Japan

On February 5, 2026, Sky Labs Inc., led by CEO Jack Byunghwan Lee, announced a significant milestone in its journey of global expansion. The company has secured an exclusive agreement with Otsuka Pharmaceutical Co., Ltd. to distribute its innovative ring-type blood pressure monitor, CART BP pro, across Japanese hospitals and clinics. This partnership represents a pivotal moment for Sky Labs as it seeks to broaden its reach in the healthcare market.

The collaboration follows a memorandum of understanding signed between the two companies in December 2024, which initially opened the doors for discussions. Leveraging Otsuka’s well-established presence in Japan, Sky Labs aims to position CART BP pro as a vital tool in hypertension management amidst a country where about 43 million individuals suffer from hypertension. Strikingly, around 29% of these patients remain uncontrolled, signaling the urgent need for reliable monitoring solutions.

Otsuka, recognized for its significant contributions to global health, provides a diverse range of medical solutions that underscore its standing in Japan's healthcare landscape. This partnership will not only facilitate smoother distribution channels but will also enhance patient accessibility to advanced healthcare technology. The CART BP pro is positioned to improve blood pressure monitoring methods significantly and is expected to encourage better health outcomes for hypertensive patients.

With clinical studies linking abnormal blood pressure patterns to severe health risks, the need for innovative monitoring technology becomes apparent. CART BP pro utilizes advanced photoplethysmography (PPG) technology that allows for painless and uninterrupted blood pressure monitoring, contrasting sharply with traditional methods that rely on cuff inflation—often causing discomfort or disrupting patient activities. Patients can comfortably measure blood pressure during regular activities and even while sleeping, ensuring stable and accurate data collection for medical professionals.

The success of CART BP pro isn't just a theory; it is backed by robust evidence from the South Korean market, where the device has received approval from the Ministry of Food and Drug Safety (MFDS) and has already accumulated over 150,000 prescriptions within a year of launch. Prescribed in over 1,700 medical institutions, CART BP pro has gained significant traction and clinical reliability, making it a compelling solution for managing hypertension.

As Jack Byunghwan Lee noted in his announcement, “Beginning with our entry into Japan, we will continue to validate our unmatched blood pressure monitoring technology in the global market while paving the way as a leader in the industry.” This sentiment captures the ambitious trajectory of Sky Labs as they navigate new markets and face the challenges of healthcare innovation.

Thus, the partnership with Otsuka Pharmaceutical not only expands the market for CART BP pro but also serves as an illustration of successful collaboration between a Korean venture and a multinational corporation. This endeavor marks a critical step in the global distribution of advanced healthcare solutions and highlights the increasing importance of innovative technologies in managing chronic health conditions effectively.

In summary, the exclusive distribution agreement sets the stage for a broader adoption of CART BP pro in Japan, aiming to improve health outcomes through enhanced monitoring technology and accessibility to effective treatment strategies.